Collecting blood samples to study sickle cell disease
High Sensitivity Screening of Compound Libraries to Discover a Drug for the Treatment of Sickle Cell Disease
This study is collecting blood samples from healthy people and those with sickle cell disease to see if new drugs can help stop red blood cells from sickling.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 250 (estimated) |
| Ages | 18 Years to 100 Years |
| Sex | All |
| Sponsor | National Institutes of Health Clinical Center (CC) NIH |
| Locations | 1 site (Bethesda, Maryland) |
| Trial ID | NCT00542230 on ClinicalTrials.gov |
What this trial studies
This observational study aims to collect blood samples from both healthy individuals and those with unique red blood cell features related to sickle cell disease. The goal is to investigate potential new drug treatments for sickle cell disease by analyzing these samples. Participants will undergo a one- to two-hour outpatient procedure at the National Institutes of Health Clinical Center, where they will donate small volumes of blood for high throughput screening tests. The study focuses on identifying compounds that can inhibit the sickling of red blood cells, which is a critical issue in sickle cell disease.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with sickle cell trait, known hemoglobinopathies, or healthy volunteers for control purposes.
Not a fit: Patients who are unable to comprehend the investigational nature of the research or those with HIV, Hepatitis B, or Hepatitis C will not benefit from this study.
Why it matters
Potential benefit: If successful, this research could lead to the development of new and more effective treatments for sickle cell disease.
How similar studies have performed: Other studies have shown promise in identifying new treatments for sickle cell disease, but this specific approach of high throughput screening is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
* INCLUSION CRITERIA: * Patients with sickle cell trait * Patients with known hemoglobinopathies involving one or two genes for sickle hemoglobin * Healthy volunteers for control experiments * Age range: adults greater than or equal to 18 years of age EXCLUSION CRITERIA: * Subjects who are unable to comprehend the investigational nature of the laboratory research are ineligible to enroll in this protocol. * As a safety precaution in handling the blood samples, patients with HIV, Hepatitis B or Hepatitis C will be excluded from the study. HIV, Hepatitis B or Hepatitits C testing will not be done under this study. Participants must be co-enrolled under another NIH protocol where the screening evaluation has been performed.
Where this trial is running
Bethesda, Maryland
- National Institutes of Health Clinical Center — Bethesda, Maryland, United States (Recruiting)
Study contacts
- Principal investigator: William A Eaton, M.D. — National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Study coordinator: William A Eaton, M.D.
- Email: eaton@mail.nih.gov
- Phone: (301) 496-6030
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.